Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone Response and Toxicity in Prostate Cancer
NCT03348670Phase 3Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa). Started Aug 2023; status: active, not recruiting.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03348670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03348670.